RxDoctor Payments Data

Stephen Purser, MD

Family Medicine · Charleston, SCNPI 1083148423

Payments from drug & device makers

$1,755in general payments, 2019–2025

Across 92 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$538
  • Lilly USA, LLC$288
  • Alkermes, Inc.$192
  • AstraZeneca$142
  • Merck$121
  • Sanofi-aventis U.S. LLC$79
  • plus $396 from 12 others

What the payments were for

  • Consulting fees$1217%
  • Food & beverage$1,63493%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,755 in reported general payments places this provider in the 70th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$64,430
Medicare patients
238
Services billed
998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide45$45,135
JardianceEmpagliflozin33$39,632
OzempicSemaglutide31$36,458
EliquisApixaban24$23,453
FarxigaDapagliflozin Propanediol14$20,552
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$19,398
VraylarCariprazine Hcl11$14,961
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,602
LinzessLinaclotide12$10,425
Combivent RespimatIpratropium/Albuterol Sulfate12$8,567
TrintellixVortioxetine Hydrobromide13$6,811
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl34$4,656
VascepaIcosapent Ethyl13$4,075
Varenicline Tartrate14$3,940
Novolog FlexpenInsulin Aspart15$3,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$288$45,13545 claims
Novo NordiskOzempic$24$36,45831 claims
AbbVieVraylar, Linzess$538$25,38523 claims
PfizerEliquis$61$23,45324 claims
AstraZenecaFarxiga$142$20,55214 claims
GSKTrelegy Ellipta$65$12,60215 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$20$6,81113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →